Human PD-1, Fc Tag (PD1-H5257) is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Gln 167 (Accession # NP_005009.2).
N-terminal Sequence Analysis: Leu 25
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 42.6 kDa. The protein migrates as 56-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Less than 0.1 EU per μg by the LAL method.
>95% as determined by SDS-PAGE.
>90% as determined by SEC-HPLC.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
- 4-8°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Human PD-1, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Human PD-1, Fc Tag (HPLC-verified)(Cat. No. PD1-H5257) was greater than 90% as determined by SEC-HPLC.
Immobilized Biotinylated Human PD-L1 (recommended for biopanning), His Tag, Avi Tag (Cat. No. PD1-H82E5) at 1 μg/mL (100 μL/well) on streptavidin precoated (0.2μg/well) plate, can bind Human PD-1, Fc Tag (Cat. No. PD1-H5257) with a linear range of 0.1-3 ng/mL (QC tested).
Immobilized Human PD-1, Fc Tag (Cat. No. PD1-H5257) at 2 μg/mL (100 μL/well) can bind Biotinylated Human PD-L2, Fc Tag, Avi Tag (Cat. No. PD2-H82F6) with a linear range of 0.5-16 ng/mL. (Routinely tested).
Immobilized Biotinylated Human PD-L2, His Tag (Cat. No. PD2-H82E8) at 1 μg/mL (100 μL/well) on streptavidin precoated (0.2μg/well) plate, can bind Human PD-1, Fc Tag (Cat. No. PD1-H5257) with a linear range of 0.1-1 ng/mL (Routinely tested).
Human PD-1, Fc Tag (Cat. No. PD1-H5257) captured on CM5 chip via anti-human IgG Fc antibody, can bind Human PD-L1, His Tag (HPLC-verified) (Cat. No. PD1-H5229) with an affinity constant of 3.6 μM as determined in a SPR assay (Biacore T200) (Routinely tested).
Flow Cytometry assay shows that recombinant Human PD-1, Fc Tag (Cat. No. PD1-H5257) can bind to 293 cell overexpressing human PD-L1. The concentration of PD-1 used is 1 μg/mL (Routinely tested).
Authors: Fromm G, et al
Journal: J ImmunoTher Cancer 43452
Authors: P Liu, et al.
Journal: US20180177870A1 2018
Application: Alphascreen & HTRF assay
Authors: Wang Aijun, et al.
Journal: US20170355770A1 2017
Authors: Zhenwu Li, et al.
Journal: US20170320875A1 2017
Application: HTRF Binding Assay
Authors: J Li, et al.
Journal: US20170145025A1 2017
Application: HTRF Binding Assay
Authors: Lai WY, et al.
Journal: Mol Ther Nucleic Acids 2016
Application: ELISA-based competition assay
Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer.